Voabil, Paula
de Bruijn, Marjolein http://orcid.org/0000-0002-2142-4684
Roelofsen, Lisanne M. http://orcid.org/0000-0001-7686-1614
Hendriks, Sanne H. http://orcid.org/0000-0002-0974-3666
Brokamp, Simone
van den Braber, Marlous
Broeks, Annegien
Sanders, Joyce http://orcid.org/0000-0002-0551-7813
Herzig, Petra
Zippelius, Alfred http://orcid.org/0000-0003-1933-8178
Blank, Christian U. http://orcid.org/0000-0002-7945-5846
Hartemink, Koen J.
Monkhorst, Kim
Haanen, John B.A.G. http://orcid.org/0000-0001-5884-7704
Schumacher, Ton N. http://orcid.org/0000-0003-0517-8804
Thommen, Daniela S. http://orcid.org/0000-0002-7431-2854
Article History
Received: 28 April 2020
Accepted: 17 May 2021
First Online: 8 July 2021
Competing interests
: T.N.S. is an advisor to Adaptive Biotechnologies, Allogene Therapeutics, Merus, Neogene Therapeutics and Scenic Biotech. He is a recipient of research support from Merck KGaA, a stockholder in Allogene Therapeutics, Merus, Neogene Therapeutics and Scenic Biotech and is venture partner at Third Rock Ventures, all outside of the current work. D.S.T. received research funding from Bristol Myers Squibb, outside of the current work. The other authors declare no competing interests.